Fabry
58 programs · 55 companies
Programs
58
Companies
55
Trials
46
MOAs
39
Anti-TauKRASG12CiJAK1/2iJAK1iBTKiAuroraAiFcRniCD47iGLP-1agPI3Ki
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Phase 1 | SGLT2 | ||
| AZN-8478 | NDA/BLA | SHP2 | ||
| VRT-9481 | Phase 1/2 | Menin | ||
| Adagratapinarof | Preclinical | BCMA | ||
| MRN-8133 | Phase 2 | PD-1 | ||
| MRN-5715 | NDA/BLA | CDK4/6 | ||
| Zanufutibatinib | NDA/BLA | CD38 | ||
| DNL-9555 | Phase 1/2 | KIF18A | ||
| Semamavacamten | Phase 1/2 | AuroraA | ||
| CGO-9628 | Phase 2/3 | AuroraA | ||
| Polazanubrutinib | Phase 1 | IL-17A | ||
| Teraosocimab | Phase 3 | GPRC5D | ||
| UCB-6099 | Approved | SHP2 | ||
| DAN-IIT-542 | Phase 2 | LAG-3 | ||
| Voxavorutinib | NDA/BLA | TIGIT | ||
| QUO-7972 | NDA/BLA | BCMA | ||
| Lisorasimod | Phase 2/3 | EGFR | ||
| Nidavorutinib | NDA/BLA | KRASG12C | ||
| ASM-5108 | Phase 1 | TYK2 | ||
| ALD-9169 | Preclinical | JAK1 | ||
| Talatuximab | Phase 1/2 | SHP2 | ||
| Lisoderotide | Phase 3 | SHP2 | ||
| MRN-6769 | Phase 2/3 | PD-1 | ||
| Ribomavacamten | Phase 3 | EZH2 | ||
| Ribotinib | Phase 1 | SGLT2 | ||
| Cevitapinarof | Phase 2/3 | GIP-R | ||
| PRO-7290 | Phase 2/3 | B7-H3 | ||
| Doxazanubrutinib | Phase 3 | MALT1 | ||
| ORC-1969 | Phase 1 | Tau | ||
| SHI-2889 | Phase 2 | CFTR | ||
| Polalucimab | Phase 2 | CDK4/6 | ||
| Nidazumab | Phase 2 | CFTR | ||
| Miriderotide | Phase 1/2 | GPRC5D | ||
| Datocapivasertib | NDA/BLA | PD-1 | ||
| Mirisertib | Phase 3 | CD19 | ||
| Polamavacamten | NDA/BLA | HER2 | ||
| 415-3897 | Phase 3 | GLP-1R | ||
| 456-7078 | Phase 1/2 | TIM-3 | ||
| Ivorasimod | Phase 3 | HER2 | ||
| NOI-8348 | Preclinical | Menin | ||
| 006-348 | Phase 1/2 | CD38 | ||
| GLO-9650 | Phase 2 | RET | ||
| Zenosertib | Phase 2/3 | FXIa | ||
| Sotozanubrutinib | Phase 2/3 | IL-23 | ||
| Zorirasimod | Phase 1/2 | B7-H3 | ||
| Ivomavacamten | Phase 1/2 | AHR | ||
| DAR-2860 | Phase 1 | GLP-1R | ||
| Polamavacamten | Phase 1/2 | FGFR | ||
| Motazumab | Phase 3 | PARP | ||
| Elrasacituzumab | Phase 2/3 | EGFR | ||
| AIP-7637 | NDA/BLA | GPRC5D | ||
| KAR-IIT-192 | Phase 3 | CDK4/6 | ||
| NAT-IIT-130 | Phase 1/2 | EGFR | ||
| WST-9696 | Phase 3 | PCSK9 | ||
| POL-7277 | Phase 1 | TIGIT | ||
| DYN-9663 | Approved | GPRC5D | ||
| CER-9073 | Phase 1 | JAK1 | ||
| VEE-8520 | NDA/BLA | ALK |
Trials (46)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03549234 | RHH-7558 | Phase 1 | Completed |
| NCT04306336 | AZN-8478 | NDA/BLA | Not yet recr... |
| NCT06989870 | MRN-8133 | Phase 2 | Recruiting |
| NCT08081219 | MRN-8133 | Phase 2 | Recruiting |
| NCT08963635 | MRN-5715 | NDA/BLA | Active |
| NCT08132646 | Semamavacamten | Phase 1/2 | Not yet recr... |
| NCT06609724 | CGO-9628 | Phase 2/3 | Recruiting |
| NCT03569640 | Polazanubrutinib | Phase 1 | Terminated |
| NCT08799303 | Polazanubrutinib | Phase 1 | Recruiting |
| NCT05900099 | Teraosocimab | Phase 3 | Recruiting |
| NCT05337102 | UCB-6099 | Approved | Terminated |
| NCT03484162 | DAN-IIT-542 | Phase 2 | Completed |
| NCT03829209 | Voxavorutinib | NDA/BLA | Active |
| NCT03380931 | Lisorasimod | Phase 2/3 | Recruiting |
| NCT07528427 | Lisorasimod | Phase 2/3 | Completed |
| NCT06706472 | ALD-9169 | Preclinical | Recruiting |
| NCT08740738 | ALD-9169 | Preclinical | Recruiting |
| NCT05381892 | Talatuximab | Phase 1/2 | Recruiting |
| NCT06921393 | Lisoderotide | Phase 3 | Completed |
| NCT03993033 | Lisoderotide | Phase 3 | Not yet recr... |